TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34504284

Group type: EXPERIMENTAL
Intervention: rTMS (20 Hz, 1800 pulses per session) for 4 weeks before lower limb resistance training or physical therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 20
Study: 33475984

Group type: EXPERIMENTAL
Intervention: Sublingual fentanyl tablet
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 33754424

Group type: EXPERIMENTAL
Intervention: Levobupivacaine HCl (5.0 mg/mL) mixed with isotonic solution (4, 6, 8, and 10 mL of levobupivacaine with 26, 24, 22, and 20 mL of isotonic solution, respectively)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Levobupivacaine HCl (5.0 mg/mL) mixed with isotonic solution
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group using Cathejell-2% lidocaine (25 mg lidocaine)
Number of subjects: 100
Study: 32565123

Group type: EXPERIMENTAL
Intervention: Swimming
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cycling
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study: 32409696

Group type: EXPERIMENTAL
Intervention: Highest quartile of PR interval
Number of subjects: 1722

Group type: EXPERIMENTAL
Intervention: CAV1 SNP
Number of subjects: 1722

Group type: EXPERIMENTAL
Intervention: CAV1 SNP (Mendelian randomization)
Number of subjects: 1722
Study: 33830082

Group type: EXPERIMENTAL
Intervention: Inhibition of miR-122 in the lung
Number of subjects: 87

Group type: COMPARATOR
Intervention: Higher miR-122 expression in nasopharyngeal aspirates
Number of subjects: 87
Study: 33645399

Group type: EXPERIMENTAL
Intervention: LASER Artificial Shrinkage (LAS)
Number of subjects: 409

Group type: COMPARATOR
Intervention: Micro-Needle Artificial Shrinkage (MNAS)
Number of subjects: 409
Study: 34102783

Group type: EXPERIMENTAL
Intervention: Intranasal glucocorticoid (dexamethasone) after nasal endoscopic surgery
Number of subjects: 122

Group type: COMPARATOR
Intervention: Oral glucocorticoid (prednisone) one week before operation and three weeks after operation
Number of subjects: 122
Study: 35322424

Group type: COMPARATOR
Intervention: Traditional conclusion scale
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Strength-of-support conclusion scale
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Expanded scale
Number of subjects: 60
Study: 32890339

Group type: EXPERIMENTAL
Intervention: Group A emergency-release plasma (ERP)
Number of subjects: 584

Group type: COMPARATOR
Intervention: Group AB emergency-release plasma (ERP)
Number of subjects: 584

Group type: EXPERIMENTAL
Intervention: Incompatible ERP (group B or AB patients receiving group A ERP)
Number of subjects: 584
Study: 32207667

Group type: EXPERIMENTAL
Intervention: Family Check Up (FCU)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Brief Psychoeducation (PE)
Number of subjects: 102
Study: 34503552

Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplant (AHSCT) treatment
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Modifiable factors (distance to treatment center and cost)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Predicted recruitment rates
Number of subjects: 278
Study: 36030986

Group type: EXPERIMENTAL
Intervention: Osc+ condition (biofeedback to increase heart rate oscillations)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Osc− condition (biofeedback to decrease heart rate oscillations)
Number of subjects: 0
Study: 33874838

Group type: EXPERIMENTAL
Intervention: Listening to music during warm-up after partial sleep deprivation (PSD)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Listening to music during warm-up after normal sleep nights (NSN)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Partial sleep deprivation (PSD)
Number of subjects: 12
Study: 36145115

Group type: EXPERIMENTAL
Intervention: 15 g of ground raw golden flaxseed
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standardized breakfast without flaxseed (control)
Number of subjects: 19
Study: 33334807

Group type: COMPARATOR
Intervention: CGM+FBI
Number of subjects: 143

Group type: COMPARATOR
Intervention: Standard‐CGM
Number of subjects: 143

Group type: COMPARATOR
Intervention: BGM
Number of subjects: 143

Group type: COMPARATOR
Intervention: CGM+FBI parents
Number of subjects: 143
Study: 34894724

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 32056864

Group type: EXPERIMENTAL
Intervention: PROMIS depression scales
Number of subjects: 651
Study: 33120302

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 182

Group type: COMPARATOR
Intervention: Ketamine
Number of subjects: 182

Group type: COMPARATOR
Intervention: Combination of haloperidol and ketamine
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Postoperative cortisol levels
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: S-100β levels
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: Postoperative NSE levels
Number of subjects: 182
Study: 32344198

Group type: EXPERIMENTAL
Intervention: Ileo-colonic delivery of conjugated bile acids (IC-CBAS)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study: 36497548

Group type: EXPERIMENTAL
Intervention: Multi-component exercise (MCE)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 34170389

Group type: EXPERIMENTAL
Intervention: Pegaspargase (3000 IU/m2 IV) during induction
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Pegaspargase (2500 IU/m2 or 3500 IU/m2 IV intermittently)
Number of subjects: 482

Group type: COMPARATOR
Intervention: Pegaspargase vs Erwinase
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Serum asparaginase activity
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: CSF asparagine depletion
Number of subjects: 482
Study: 32949650

Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring (CGM)
Number of subjects: 279
Study: 35426136

Group type: EXPERIMENTAL
Intervention: Daridorexant 50 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Daridorexant 100 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Zopiclone 7.5 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Daridorexant (both doses)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Daridorexant
Number of subjects: 60
Study: 34171555

Group type: EXPERIMENTAL
Intervention: Escitalopram (verum group)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 181
Study: 34232704

Group type: EXPERIMENTAL
Intervention: Speaking fundamental frequency (fos)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Vowel formant frequencies (F1, F2, F3)
Number of subjects: 379

Group type: COMPARATOR
Intervention: Listener perceptions of speaker gender
Number of subjects: 379
Study: 36295519

Group type: EXPERIMENTAL
Intervention: High-dose intramuscular vitamin D (cholecalciferol 200,000 IU)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Standard of care (alfacalcidol 1 mcg/day)
Number of subjects: 116
Study: 33468283

Group type: EXPERIMENTAL
Intervention: Behaviourally focused nutrition education intervention (weekly sessions for 12 weeks)
Number of subjects: 498

Group type: COMPARATOR
Intervention: Control group (no sessions conducted)
Number of subjects: 498

Group type: EXPERIMENTAL
Intervention: Behaviourally focused nutrition education intervention
Number of subjects: 498
Study: 32327729

Group type: EXPERIMENTAL
Intervention: Ixazomib
Number of subjects: 489

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Deepening responses (Ixazomib)
Number of subjects: 489

Group type: COMPARATOR
Intervention: Deepening responses (Placebo)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Without deepening responses (Ixazomib)
Number of subjects: 489

Group type: COMPARATOR
Intervention: Without deepening responses (Placebo)
Number of subjects: 489
Study: 33355028

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) plus usual care
Number of subjects: 411

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 411
Study: 33990993

Group type: EXPERIMENTAL
Intervention: Anti-cancer drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional standard therapies
Number of subjects: 0
Study: 32241810

Group type: EXPERIMENTAL
Intervention: 30 mL/kg/day feed advancement
Number of subjects: 2468

Group type: COMPARATOR
Intervention: 18 mL/kg/day feed advancement (control)
Number of subjects: 2468
Study: 36217901

Group type: COMPARATOR
Intervention: RP7214 single dose (100, 200, and 400 mg QD)
Number of subjects: 42

Group type: COMPARATOR
Intervention: RP7214 multiple doses (200 and 400 mg BID for 7 days)
Number of subjects: 42

Group type: COMPARATOR
Intervention: RP7214 single dose (200 mg) food effect study
Number of subjects: 42
Study: 33172305

Group type: EXPERIMENTAL
Intervention: Bolstered standard of care plus family economic empowerment intervention
Number of subjects: 702

Group type: COMPARATOR
Intervention: Bolstered standard of care
Number of subjects: 702
Study: 34887236

Group type: EXPERIMENTAL
Intervention: FPBB+LLLT
Number of subjects: 42

Group type: COMPARATOR
Intervention: UCG
Number of subjects: 42
Study: 33714796

Group type: EXPERIMENTAL
Intervention: HPV infection cohort
Number of subjects: 30001

Group type: COMPARATOR
Intervention: Control cohort (patients without HPV infection)
Number of subjects: 30001
Study: 32694454

Group type: EXPERIMENTAL
Intervention: Comprehensive Cardiac Rehabilitation (CCR)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Exercise-only CR
Number of subjects: 115

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 115
Study: 36463269

Group type: EXPERIMENTAL
Intervention: Joint nomogram incorporating clinical factors and radiomic signature
Number of subjects: 299

Group type: COMPARATOR
Intervention: Clinical nomogram
Number of subjects: 299

Group type: COMPARATOR
Intervention: Radiomics predictive models
Number of subjects: 299

Group type: COMPARATOR
Intervention: Joint nomogram vs Clinical nomogram
Number of subjects: 299
Study: 32993380

Group type: EXPERIMENTAL
Intervention: Hydrophobic acrylic IOL (iPure, PhysIOL)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Hydrophobic acrylic control IOL (Tecnis ZCB00, Johnson&Johnson)
Number of subjects: 31
Study: 36395131

Group type: EXPERIMENTAL
Intervention: Real tDCS
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 15
Study: 34192893

Group type: COMPARATOR
Intervention: Atorvastatin 10 mg for 3.3 years
Number of subjects: 8580

Group type: EXPERIMENTAL
Intervention: Amlodipine-based regimen for 5.5 years
Number of subjects: 8580

Group type: EXPERIMENTAL
Intervention: BP variability (SD mean BP)
Number of subjects: 8580
Study: 33067624

Group type: EXPERIMENTAL
Intervention: HLA epitope‐matched (HEM) platelets
Number of subjects: 49

Group type: COMPARATOR
Intervention: HLA standard antigen‐matched (HSM) platelets
Number of subjects: 49
Study: 34724457

Group type: EXPERIMENTAL
Intervention: Melatonin (6 mg)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 36011699

Group type: EXPERIMENTAL
Intervention: Packaged operation and maintenance interventions in Roxas City schools
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group in Passi City schools
Number of subjects: 30
Study: 32979877

Group type: EXPERIMENTAL
Intervention: 100% autogenous bone (AB)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 50% deproteinized bovine bone matrix (DBBM)/ 50% autogenous bone (BOAB)
Number of subjects: 30
Study: 35106590

Group type: EXPERIMENTAL
Intervention: HP501 (45 mg) administered over 10 days to hyperuricemic patients
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: HP501 (doses from 5 to 60 mg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: HP501 and febuxostat combination
Number of subjects: 100
Study: 35507345

Group type: EXPERIMENTAL
Intervention: EPICC (Empowering Patients in Chronic Care) intervention, which included 6 group sessions and individual motivational interviewing sessions.
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: EPICC (Empowering Patients in Chronic Care) intervention during maintenance phase.
Number of subjects: 280

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC) with diabetes education.
Number of subjects: 280
Study: 32532249

Group type: EXPERIMENTAL
Intervention: HABIT‐ILE (50 hours over 2 weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Regular motor activity and/or customary rehabilitation
Number of subjects: 50
Study: 35106827

Group type: EXPERIMENTAL
Intervention: Non-anticoagulant therapy in patients with AF
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: AF duration > 3 years
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Exosome concentrations of T-tau and Aβ42 in the CI group
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Serum concentrations of IL-6 and MMP-9 in patients with AF
Number of subjects: 260
Study: 33475958

Group type: EXPERIMENTAL
Intervention: Proposed method for single cell clustering using UMAP and k-means algorithm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control method not specified
Number of subjects: 0
Study: 32152642

Group type: EXPERIMENTAL
Intervention: Isokinetic eccentric training + whey protein isolate
Number of subjects: 37

Group type: COMPARATOR
Intervention: Isokinetic eccentric training
Number of subjects: 37
Study: 33106609

Group type: EXPERIMENTAL
Intervention: Intensive statin treatment
Number of subjects: 157

Group type: COMPARATOR
Intervention: Standard statin treatment
Number of subjects: 157
Study: 32990012

Group type: EXPERIMENTAL
Intervention: Single-incision mesh (MESH)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Sacrospinous ligament fixation (ACSSF)
Number of subjects: 146
Study: 35857716

Group type: EXPERIMENTAL
Intervention: Amphetamine Extended-Release Tablets (AMPH ER TAB) 5 mg starting dose, increased to 20 mg for 14±3 days before visit 5.
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo, matching the AMPH ER TAB.
Number of subjects: 130
Study: 33956056

Group type: EXPERIMENTAL
Intervention: Dapirolizumab pegol (DZP) 6/24/45 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dapirolizumab pegol (DZP)
Number of subjects: 0
Study: 33272291

Group type: EXPERIMENTAL
Intervention: COVID-19 patients
Number of subjects: 63

Group type: COMPARATOR
Intervention: non-COVID-19 patients
Number of subjects: 63
Study: 34474447

Group type: EXPERIMENTAL
Intervention: Anterior cervical discectomy and arthroplasty (ACDA)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Anterior cervical discectomy (ACD)
Number of subjects: 251
Study: 32340597

Group type: EXPERIMENTAL
Intervention: Provider-supported care
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Self-directed care
Number of subjects: 859
Study: 35737687

Group type: EXPERIMENTAL
Intervention: Physical activity (PA) telephone coaching intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 34107772

Group type: EXPERIMENTAL
Intervention: Laser plus DCB
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (POBA)
Number of subjects: 61
Study: 32995892

Group type: EXPERIMENTAL
Intervention: Exenatide (EX) 10-20μg daily
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Combination (COM) of Exenatide and Metformin
Number of subjects: 150

Group type: COMPARATOR
Intervention: Metformin (MET) 1500-2000 mg daily
Number of subjects: 150
Study: 32048890

Group type: EXPERIMENTAL
Intervention: RIBSP vaccine
Number of subjects: 150

Group type: COMPARATOR
Intervention: VAXIGRIP® vaccine
Number of subjects: 150
Study: 35155345

Group type: EXPERIMENTAL
Intervention: Mentorship as an intervention to address workplace hazards
Number of subjects: 19

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 19
Study: 33096665

Group type: EXPERIMENTAL
Intervention: Air purifiers with filter on
Number of subjects: 26

Group type: COMPARATOR
Intervention: Air purifiers with filter off
Number of subjects: 26
Study: 35910353

Group type: EXPERIMENTAL
Intervention: Ivermectin/albendazole 18/400 mg (1 tablet)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Ivermectin 3 mg (6 tablets)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Albendazole 400 mg (1 tablet)
Number of subjects: 78
Study: 35165297

Group type: EXPERIMENTAL
Intervention: Ferric citrate hydrate (FC)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Non-iron-based phosphate binders (Control)
Number of subjects: 82
Study: 35005202

Group type: EXPERIMENTAL
Intervention: Application‐based Cognitive Training at Home (ACTH) for 12 months
Number of subjects: 389

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 389
Study: 32705834

Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with moxibustion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral administration of Jingui Shenqi pills and Suoquan capsules
Number of subjects: 60
Study: 34515619

Group type: EXPERIMENTAL
Intervention: Yakson
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Gentle human touch
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study: 32440738

Group type: EXPERIMENTAL
Intervention: Collaborative care (n=41)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Usual care (n=51)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 92
Study: 36297036

Group type: EXPERIMENTAL
Intervention: 3 mg/kg of p-synephrine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 18
Study: 33551687

Group type: EXPERIMENTAL
Intervention: Visual Simple Reaction Time (SRT) measured at three different times of the day (10 a.m., 1 p.m., and 5 p.m.)
Number of subjects: 20
Study: 34614121

Group type: EXPERIMENTAL
Intervention: 0.018-inch NiTi archwire
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.014-inch NiTi archwire
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.016-inch NiTi archwire
Number of subjects: 40
Study: 32960999

Group type: EXPERIMENTAL
Intervention: Bladder Training (BT) + Electrical Stimulation (ES)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Bladder Training (BT) + Biofeedback (BF) + Electrical Stimulation (ES)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Bladder Training (BT) + Biofeedback (BF)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Bladder Training (BT) alone
Number of subjects: 70
Study: 34407575

Group type: EXPERIMENTAL
Intervention: Licofor
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 60
Study: 36350349

Group type: EXPERIMENTAL
Intervention: empowerED
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study: 34406598

Group type: EXPERIMENTAL
Intervention: One Anastomosis Gastric Bypass (OAGB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Roux-en-Y Gastric Bypass (RYGB)
Number of subjects: 80
Study: 33390295

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine approval announced one week before the presidential election
Number of subjects: 0

Group type: COMPARATOR
Intervention: COVID-19 vaccine approval announced one week after the presidential election
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endorsement by Dr. Anthony Fauci
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endorsement by Dr. Anthony Fauci with pre-election vaccine approval
Number of subjects: 0
Study: 33389320

Group type: EXPERIMENTAL
Intervention: Daily oral pre-exposure prophylaxis and adherence support
Number of subjects: 193
Study: 35334049

Group type: EXPERIMENTAL
Intervention: Simulated acid rain (pH 5.0, 4.0, and 3.0)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Control treatment (pH 6.0)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Brassica rapa (at pH 3.0)
Number of subjects: 3
Study: 33719503

Group type: EXPERIMENTAL
Intervention: Speech Intelligibility Treatment (SIT)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hand‐Arm Bimanual Intensive Therapy Including Lower Extremities (PT)
Number of subjects: 10
Study: 32343977

Group type: EXPERIMENTAL
Intervention: Antireflux ablation therapy (ARAT)
Number of subjects: 108
Study: 35961933

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Desktop Interfaces (DI)
Number of subjects: 50
Study: 32525464

Group type: EXPERIMENTAL
Intervention: Individualized blood pressure lowering treatment
Number of subjects: 483

Group type: COMPARATOR
Intervention: Standard blood pressure lowering treatment
Number of subjects: 483
Study: 32417382

Group type: COMPARATOR
Intervention: IV Lorazepam (LZP)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: IV Brivaracetam 100 mg
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: IV Brivaracetam 200 mg
Number of subjects: 46
Study: 35352835

Group type: EXPERIMENTAL
Intervention: Anifrolumab 300 mg Q4W
Number of subjects: 819

Group type: EXPERIMENTAL
Intervention: Anifrolumab 150 mg Q4W
Number of subjects: 819

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 819
Study: 34782024

Group type: EXPERIMENTAL
Intervention: Robotic-based upper-limb reaching task with robot-generated haptic guidance and audio-visual feedback
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group with similar robotic training but without vision occluded and robot-generated cues
Number of subjects: 30
Study: 34125340

Group type: EXPERIMENTAL
Intervention: Trastuzumab-dkst
Number of subjects: 242

Group type: COMPARATOR
Intervention: Trastuzumab
Number of subjects: 242
Study: 33496122

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine formula (CHMF)
Number of subjects: 41
Study: 36317791

Group type: EXPERIMENTAL
Intervention: Chitogel
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Chitogel + Def + GaPP
Number of subjects: 82

Group type: COMPARATOR
Intervention: No packing (control)
Number of subjects: 82
Study: 32072468

Group type: EXPERIMENTAL
Intervention: Universal test and treat (UTT) approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expanded provision of ART
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study: 35815898

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 2062

Group type: COMPARATOR
Intervention: Appendectomy
Number of subjects: 2062